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that traverses these gap junctions 
during instructive left-right pattern-
ing. Based on existing data, strong 
candidates include electrical cur-
rents, Ca2+, and serotonin (which is 
thought to be the morphogen that 
moves through gap junctions during 
establishment of frog asymmetry; 
Levin, 2006). The relationship of this 
pathway to other known components 
that establish C. elegans asymmetry 
(such as Notch signaling and the ASE 
system) also remains to be worked 
out. Most crucially, are other innex-
ins involved? With the discovery that 
even a species in which cell lineages 
are highly determined uses gap junc-
tions as part of its repertoire for gen-
erating left-right asymmetry, it is clear 
that additional surprises await us in 
the exploration of physiological inter-
cellular signals in the establishment 
of laterality.
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Inositol pyrophosphates are unique signaling molecules implicated in the regulation of 
diverse cellular processes. Two new studies by Mulugu et al. (2007) and Lee et al. (2007) 
extend the biological and metabolic diversity of this class of molecules. They identify yeast 
Vip1 as a new inositol pyrophosphate synthase and show that the products of Vip1 activity 
regulate a cyclin/cyclin-dependent kinase complex.The fully phosphorylated six-car-
bon ring of IP6 (phytic acid) was 
thought to represent the end point 
of inositol phosphorylation. The dis-
covery of inositol phosphate spe-
cies with seven (diphosphoinositol 
 pentakisphosphate; PP-IP5; IP7) or 
eight phosphates (bis-diphosphoi-
nositol tetrakisphosphate; [PP]2-IP4; 
IP8) on the inositol ring was excit-
ing and unexpected (Menniti et al., 
1993; Stephens et al., 1993). These 
“high-energy” molecules have been 
linked to a wide range of biologi-
cal functions, including vesicle traf-ficking, apoptosis, DNA repair, tel-
omere maintenance, and the stress 
response (Bennett et al., 2006). 
Although the mechanisms of action 
of inositol pyrophosphates in these 
cellular processes remain unclear, 
IP7 has been shown to directly trans-
fer the energetic β phosphate of the 
pyrophosphate moiety to multiple 
proteins, indicating that IP7 may reg-
ulate signaling pathways through a 
new mechanism of protein phosphor-
ylation (Saiardi et al., 2004). Two new 
studies published in Science identify 
an enzyme that catalyzes the pro-Cell 129duction of inositol pyrophosphates 
(Mulugu et al., 2007) and a new target 
of regulation by IP7, a cyclin/cyclin-
dependent kinase complex (Lee et 
al., 2007).
The inositol hexakisphosphate 
kinases (IP6K) are the enzymes respon-
sible for synthesis of inositol pyrophos-
phates (Saiardi et al., 1999). They are 
highly conserved evolutionarily and at 
least one member of this enzyme fam-
ily is present in all eukaryotic genomes 
sequenced so far (Bennett et al., 
2006). Inositol pyrophosphates and 
their kinases have been predominantly , May 18, 2007 ©2007 Elsevier Inc. 647
studied in the budding yeast Saccha-
romyces cerevisiae, particularly using 
mutants lacking the single yeast IP6K, 
Kcs1. In the kcs1 deletion mutant, the 
naturally occurring inositol pyrophos-
phates IP7 and IP8 are virtually unde-
tectable. Surprisingly, an additional 
deletion of the IP7 phosphatase DDP1 
in this mutant resulted in the reappear-
ance of IP7, suggesting the existence of 
a second enzyme that can synthesize 
IP7 (York et al., 2005).
Using cell extracts prepared from 
yeast lacking both Kcs1 and DDP1, 
Mulugu et al. (2007) biochemically puri-
figure 1. the Biosynthetic Pathway of 
Inositol Pyrophosphates
Myo-inositol (shown with six hydroxyl groups: 
five equatorial and one axial at position C2) is 
the building block of inositol polyphosphates. 
Sequential kinase reactions convert IP3 to IP4, 
IP5, and IP6. The fully phosphorylated ring is 
then converted to IP7 either by the action of 
the inositol pyrophosphate synthase Kcs1, 
generating the isomer 5PP-IP4, or by the newly 
identified enzyme Vip1, generating 4/6PP-IP4.648 Cell 129, May 18, 2007 ©2007 Elsefied a second inositol pyrophosphate 
synthase, which they call Vip1. Protein 
sequence analysis revealed two con-
served domains in Vip1: an amino-ter-
minal ATP-grasp superfamily domain 
with IP6 kinase activity and a histidine 
acid-phosphatase domain in the C ter-
minus (Mulugu et al., 2007). The gener-
ation of yeast lacking Kcs1, DDP1, and 
Vip1 resulted in ablation of IP7, which 
could be restored by reintroducing 
Vip1, confirming that Vip1 produces IP7 
in vivo (Mulugu et al., 2007). The most 
important finding of the Mulugu et al. 
work is that Vip1 synthesizes a form 
of IP7 that is distinct from the isomers 
5PP-IP5 produced by human IP6K1 
(which may have similar activity to yeast 
Kcs1). The IP7 generated by Vip1 has 
the pyrophosphate moiety located at 
either the C4 or C6 position (4/6PP-IP5) 
producing enantiomers that cannot be 
distinguished (Figure 1). Vip1 and Kcs1 
together produce IP8, but it is unclear 
if Vip1 is equivalent to the previously 
isolated IP7-kinase activity (Huang et 
al., 1998).
Insight into the physiological role of 
Vip1 comes from studies of Asp1, its 
ortholog in fission yeast Schizosac-
charomyces pombe, which regulates 
actin-related protein (Arp) complexes. 
Functional analyses revealed that IP6 
kinase activity is essential for maintain-
ing cellular integrity, normal growth, 
and genetic interactions with Arp com-
plex components.
Mulugu and colleagues indisputably 
demonstrate that Vip1 is required to 
produce the IP7 present in yeast lacking 
both Kcs1 and DDP1. Given that yeast 
lacking Kcs1 have nearly undetectable 
levels of inositol pyrophosphates, how 
much of the total IP7 in cells is synthe-
sized by Vip1? This might be deter-
mined by analyzing the single mutant 
lacking Vip1 and double mutants defi-
cient in both Vip1 and DDP1. The most 
interesting characteristic of Vip1 is its 
dual domain architecture, although the 
specificity of the phosphatase domain 
has yet to be determined.
In a companion study, Lee et al. 
(2007) elegantly demonstrate that 
4/6PP-IP5, the form of IP7 generated 
by Vip1, but not 5PP-IP5, the form gen-
erated by Kcs1, is a regulator of the 
Pho80-Pho85 cyclin/cyclin-depend-vier Inc.ent kinase (CDK) complex. This CDK 
complex is a key component of the 
PHO phosphate response pathway in 
yeast. Using a biochemical approach, 
Lee et al. (2007) sought to identify 
cellular components that control the 
phosphate starvation response initi-
ated when cells are grown in media 
low in phosphate. In S. cerevisiae, the 
Pho80-Pho85 cyclin-CDK complex 
is a key regulator of the PHO signal-
ing pathway. Under high-phosphate 
conditions, the Pho80-Pho85 com-
plex is active and phosphorylates the 
transcription factor Pho4, which is 
then exported from the nucleus into 
the cytoplasm. In contrast, when cells 
are starved of phosphate, the Pho80-
Pho85 complex is inhibited, leading 
to nuclear accumulation of dephos-
phorylated Pho4 and transcription of 
PHO genes. The Pho81 CDK inhibitor 
is constitutively bound to the Pho80-
Pho85 complex and is required for its 
inhibition in response to phosphate 
limitation. Analysis of fractionated 
extracts from phosphate-starved cells 
led Lee et al. to identify a small mol-
ecule capable of inhibiting the Pho80-
Pho85 kinase activity in a Pho81-
dependent manner. This molecule is 
IP7. Importantly, inactivation of Pho80-
Pho85 by IP7 is specific because inosi-
tol and many of its phosphorylated 
derivatives did not affect kinase activ-
ity (Lee et al., 2007). That Vip1 is the 
IP6 kinase involved in controlling the 
PHO pathway was shown by assaying 
extracts from phosphate-starved cells 
lacking Kcs1 and Vip1 for their ability 
to inactivate Pho80-Pho85-Pho81. 
Only extracts from cells lacking Kcs1 
but containing Vip1 were able to inhibit 
Pho80-Pho85 in a Pho81-dependent 
manner. Furthermore, the IP7 (4/6PP-
IP5) synthesized by Vip1 inhibits the 
Pho80-Pho85 complex, whereas the 
5PP-IP5 isomer synthesized by human 
IP6K1 does not (Lee et al., 2007). 
Interestingly, IP7 levels increased in 
response to phosphate limitation, 
leading the authors to conclude that 
when cells are starved of phosphate, 
the IP7 concentration increases and 
thus inhibits the Pho80-Pho85-Pho81 
complex. However, in our laboratory, 
using a different yeast strain and 
slightly different experimental condi-
tions, we observed a decrease in IP7 
cellular concentrations in response to 
phosphate starvation (A.S., unpub-
lished data), suggesting that more 
characterization of this response may 
be necessary.
Lee et al. convincingly provide a 
link between Vip1-mediated inositol 
pyrophosphate signaling and phos-
phate metabolism. However, previous 
reports have also linked Kcs1 and its 
IP6K family members to phosphate 
metabolism, suggesting that both 
5PP-IP5 and 4/6PP-IP5 have roles in 
these processes. Indeed, the first clue 
to a relationship between inositol pyro-
phosphate signaling and phosphate 
metabolism came from the discovery 
that PiUS, a stimulator of inorganic 
phosphate uptake, was in fact IP6K2 
(Bennett et al., 2006). Then it was shown 
that inorganic phosphate uptake in 
yeast lacking Kcs1 is less efficient than 
in wild-type cells. Yeast lacking Kcs1 
also have increased expression of the 
PHO phosphate response genes and 
reduced intracellular polyphosphate 
levels (Auesukaree et al., 2005; Ben-
nett et al., 2006). Moreover, yeast lack-
ing Kcs1 constitutively express the acid The beneficial effects of vitamin A 
might have been recognized first by 
the ancient Egyptians, who treated 
eye disease with raw liver. The fact 
that they recognized a connection 
guiding ligan
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Retinoic acid—the active m
by activating the retinoic aci
strate that retinoic acid also 
(PPARβ/δ). Remarkably, retino
on cytoplasmic retinoic acid 
or survival, respectively.phosphatase PHO5, which is activated 
by Pho4, indicating that the IP7 synthe-
sized by Kcs1 also influences the PHO 
transcriptional pathway (Auesukaree 
et al., 2005). These observations may 
reflect different aspects of IP7 function 
in phosphate sensing. It is possible that 
4/6PP-IP5 mainly regulates the PHO 
pathway by protein binding, whereas 
5PP-IP5 primarily functions as a phos-
phate donor.
The two new studies raise sev-
eral exciting possibilities that could 
advance our understanding of inosi-
tol pyrophosphates and their roles 
in many different aspects of cell sig-
naling. Certainly, the notion that two 
structurally different IP7 molecules 
can have distinct cellular roles is 
intriguing and will no doubt guide the 
way to more pioneering work. In the 
past decade, a large number of inosi-
tol pyrophosphate species, not only 
IP7 and IP8, have been discovered as 
well as several inositol pyrophosphate 
synthases and phosphatases. Further 
studies into these fascinating signaling 
molecules may result in the discovery 
of other species, perhaps even pyro-
phosphorylated inositol lipids.Cell 129
between eye problems and the liver, 
which is the richest source of dietary 
vitamin A, is astonishing. Today, we 
know that vitamin A (retinol) and its 
biologically active derivatives, the 
ds to nuclear R
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retinoids (the most potent of which 
is all-trans-retinoic acid), regulate 
key processes such as inhibition 
of cell proliferation, differentiation, 
apoptosis, shaping of the embryo, 
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